These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 17062838

  • 1. Doxercalciferol treatment of secondary hyperparathyroidism.
    Dennis VC, Albertson GL.
    Ann Pharmacother; 2006 Nov; 40(11):1955-65. PubMed ID: 17062838
    [Abstract] [Full Text] [Related]

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 3. Paricalcitol, a new agent for the management of secondary hyperparathyroidism in patients undergoing chronic renal dialysis.
    Goldenberg MM.
    Clin Ther; 1999 Mar; 21(3):432-41. PubMed ID: 10321413
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism.
    Cozzolino M, Brancaccio D.
    Expert Opin Pharmacother; 2008 Apr; 9(6):947-54. PubMed ID: 18377338
    [Abstract] [Full Text] [Related]

  • 6. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
    Ross EA, Tian J, Abboud H, Hippensteel R, Melnick JZ, Pradhan RS, Williams LA, Hamm LL, Sprague SM.
    Am J Nephrol; 2008 Apr; 28(1):97-106. PubMed ID: 17914251
    [Abstract] [Full Text] [Related]

  • 7. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD.
    Coyne D, Acharya M, Qiu P, Abboud H, Batlle D, Rosansky S, Fadem S, Levine B, Williams L, Andress DL, Sprague SM.
    Am J Kidney Dis; 2006 Feb; 47(2):263-76. PubMed ID: 16431255
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Differential effects of vitamin D receptor activators on aortic calcification and pulse wave velocity in uraemic rats.
    Noonan W, Koch K, Nakane M, Ma J, Dixon D, Bolin A, Reinhart G.
    Nephrol Dial Transplant; 2008 Dec; 23(12):3824-30. PubMed ID: 18644798
    [Abstract] [Full Text] [Related]

  • 10. Secondary hyperparathyroidism in chronic kidney disease: focus on clinical consequences and vitamin D therapies.
    Hudson JQ.
    Ann Pharmacother; 2006 Sep; 40(9):1584-93. PubMed ID: 16912241
    [Abstract] [Full Text] [Related]

  • 11. Real-world doxercalciferol treatment in SHPT CKD stage 3 and 4: an analysis of change in iPTH and accordance to KDOQI recommendations.
    Kumar N, Lindberg J, David K, Morris J, Menoyo J.
    Am J Nephrol; 2009 Sep; 29(2):71-8. PubMed ID: 18689981
    [Abstract] [Full Text] [Related]

  • 12. Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis.
    Greenbaum LA, Benador N, Goldstein SL, Paredes A, Melnick JZ, Mattingly S, Amdahl M, Williams LA, Salusky IB.
    Am J Kidney Dis; 2007 Jun; 49(6):814-23. PubMed ID: 17533024
    [Abstract] [Full Text] [Related]

  • 13. Vitamin D analogues for the management of secondary hyperparathyroidism.
    Martin KJ, González EA.
    Am J Kidney Dis; 2001 Nov; 38(5 Suppl 5):S34-40. PubMed ID: 11689385
    [Abstract] [Full Text] [Related]

  • 14. Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4.
    Coburn JW, Maung HM, Elangovan L, Germain MJ, Lindberg JS, Sprague SM, Williams ME, Bishop CW.
    Am J Kidney Dis; 2004 May; 43(5):877-90. PubMed ID: 15112179
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of parathyroid hormone: a dose equivalency study of paricalcitol and doxercalciferol.
    Zisman AL, Ghantous W, Schinleber P, Roberts L, Sprague SM.
    Am J Nephrol; 2005 May; 25(6):591-5. PubMed ID: 16282676
    [Abstract] [Full Text] [Related]

  • 16. Mortality risk among hemodialysis patients receiving different vitamin D analogs.
    Tentori F, Hunt WC, Stidley CA, Rohrscheib MR, Bedrick EJ, Meyer KB, Johnson HK, Zager PG, Medical Directors of Dialysis Clinic Inc.
    Kidney Int; 2006 Nov; 70(10):1858-65. PubMed ID: 17021609
    [Abstract] [Full Text] [Related]

  • 17. Effectiveness of treatment with oral paricalcitol in patients with pre-dialysis chronic kidney disease.
    Hervás Sánchez JG, Prados Garrido MD, Polo Moyano A, Cerezo Morales S.
    Nefrologia; 2011 Nov; 31(6):697-706. PubMed ID: 22130286
    [Abstract] [Full Text] [Related]

  • 18. Cinacalcet: new drug. Secondary hyperparathyroidism: where are the clinical data?
    Prescrire Int; 2006 Jun; 15(83):90-3. PubMed ID: 16764095
    [Abstract] [Full Text] [Related]

  • 19. Opposite effects of calcitriol and paricalcitol on the parathyroid hormone-(1-84)/large carboxy-terminal-parathyroid hormone fragments ratio in patients with stage 5 chronic kidney disease.
    Monier-Faugere MC, Mawad H, Malluche HH.
    Clin J Am Soc Nephrol; 2007 Nov; 2(6):1255-60. PubMed ID: 17942766
    [Abstract] [Full Text] [Related]

  • 20. A comparison of dosing regimens of paricalcitol capsule for the treatment of secondary hyperparathyroidism in CKD stages 3 and 4.
    Abboud H, Coyne D, Smolenski O, Anger M, Lunde N, Qiu P, Hippensteel R, Pradhan RS, Palaparthy RV, Kavanaugh A, Melnick JZ, Williams LA, Batlle D.
    Am J Nephrol; 2006 Nov; 26(1):105-14. PubMed ID: 16543714
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.